Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
Pfizer |
---|---|
Information provided by: | Pfizer |
ClinicalTrials.gov Identifier: | NCT00139698 |
Efficacy, tolerability and safety of olmesartan alone or in combination with hydrochlorothiazide in the treatment of mild to moderate essential hypertension
Condition | Intervention | Phase |
---|---|---|
Essential Hypertension |
Drug: olmesartan alone or in combination with hydrochlorothiazide |
Phase III |
Study Type: | Interventional |
Study Design: | Treatment, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment, Safety/Efficacy Study |
Official Title: | A Phase III, Multicenter, Open-Label, Dose-Titrating, 16-Week Study Evaluating The Efficacy, Tolerability and Safety of Olmesartan Medoxomil 20 Mg and 40 Mg Alone or in Combination With 12.5 Mg to 25 Mg of Hydrochlorothiazide in Subjects With Mild to Moderate Essential Hypertension |
Estimated Enrollment: | 410 |
Study Start Date: | September 2005 |
Estimated Study Completion Date: | July 2006 |
Ages Eligible for Study: | 18 Years to 65 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Study Director: | Pfizer CT.gov Call Center | Pfizer |
Study ID Numbers: | A0021002 |
Study First Received: | August 29, 2005 |
Last Updated: | July 30, 2007 |
ClinicalTrials.gov Identifier: | NCT00139698 |
Health Authority: | Hong Kong: Joint CUHK-NTEC Clinical Research Ethics Committee |
Vascular Diseases Olmesartan medoxomil Essential hypertension |
Angiotensin II Hydrochlorothiazide Hypertension |
Angiotensin II Type 1 Receptor Blockers Membrane Transport Modulators Molecular Mechanisms of Pharmacological Action Natriuretic Agents Therapeutic Uses Sodium Chloride Symporter Inhibitors |
Physiological Effects of Drugs Diuretics Cardiovascular Diseases Cardiovascular Agents Antihypertensive Agents Pharmacologic Actions |